Company: IMNN
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001493152-25-022120
Chunk: 24

Company: Imunon, Inc.
Filing Date: 2025-11-13
Form: 10-Q
Item: Part I, Item 8
Chunk 24
---
 with an increase in median overall survival (OS) from 11.1 to 13 months following treatment with
IMNN-001 plus standard-of-care (SoC) neoadjuvant and adjuvant chemotherapy (NACT) versus SoC alone. More than one-third of patients
in the trial survived more than 36 months from the point of study enrollment, with 62% of those surviving patients from the IMNN-001
treatment arm and 38% from the SoC arm. Over 10% of trial participants have reached 48 months or beyond. In
April 2025, the Company announced that an IMNN-001 abstract was accepted for oral presentation at the 2025 ASCO annual meeting. The
Company also plans to submit the results for publication in a peer-reviewed medical journal.

In
June 2025, the Company announced positive data from the Company’s Phase 2 OVATION 2 Study showing that treatment with IMNN-001
in women with newly diagnosed advanced ovarian cancer resulted in consistent, clinically meaningful improvements in several key endpoints
across treatment groups, including overall survival (OS), progression-free survival (PFS), chemotherapy response score and surgical response.
Treatment with IMNN-001 also showed a favorable safety profile, with no reports of serious immune-related adverse events. The full results
were presented in an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois,
and simultaneously published in the peer-reviewed journal Gynecologic Oncology. The data presented highlighted the consistent results
achieved across all treatment groups, demonstrating: Median 13-month increase in OS and median 3-month increase in
PFS in IMNN-001 treatment arm compared to standard of care alone. Better therapeutic effect observed with IMNN-001
treatment compared to the control arm (p=0.0375), as shown by mean 6.5-month extension of time free of progression or death (PFS + OS)
captured in totality of treatment effect. Use of poly ADP-ribose polymerase (PARP) inhibitors as part of maintenance therapy further
enhanced outcomes, with median OS not yet reached in IMNN-001 treatment arm after >5 years compared to 37 months on standard of care.
Chemotherapy response score highlights double the response rate of a complete or near complete histopathological response following treatment
with 26.1% in the IMNN-001 treatment arm compared to